title: [Can serum protein S100beta predict neurological deterioration after moderate or minor traumatic brain injury?].
abstract: BACKGROUND
  Patients with moderate traumatic brain injury (TBI) (Glasgow Coma Scale, GCS, 9-13) or minor TBI (GCS 14-15) are at risk for subsequent neurological deterioration. Serum protein S-100 is believed to reflect brain damage following TBI. In patients with normal or minor CT scan abnormalities on admission, we tested whether the determination of serum protein S-100 beta could predict secondary neurological deterioration.
  
  
  METHODS
  Sixty-seven patients with moderate or minor TBI were prospectively studied. Serum samples were collected on admission within 12 hours postinjury to measure serum protein S-100 levels. Neurological outcome was assessed up to seven days after trauma. Secondary neurological deterioration was defined as two points or more decrease from the initial GCS, or any treatment for neurological deterioration.
  
  
  RESULTS
  Nine patients had a secondary neurological deterioration after trauma. No differences in serum levels of protein S-100 were found between these patients and those without neurological aggravation (n=58 patients): 0.93 microg/l (0.14-4.85) vs 0.39 microg/l (0.04-6.40), respectively. The proportion of patients with abnormal levels of serum protein S-100 at admission according to two admitted cut-off levels (>0.1 and >0.5 microg/l) was comparable between the two groups of patients. Elevated serum levels of protein S-100 were found in patients with Injury Severity Score (ISS) of more than 16 (n=23 patients): 1.26 microg/l (0.14-6.40) vs 0.22 microg/l (0.04-6.20) in patients with ISS less than 16 (n=44 patients).
  
  
  CONCLUSIONS
  The dosage of serum protein S-100 on admission failed to predict patients at risk for neurological deterioration after minor or moderate TBI. Extracranial injuries can increase serum protein S-100 levels, then limiting the usefulness of this dosage in this clinical setting.
authors.affiliation: Pôle anesthésie-réanimation, hôpital Albert-Michallon, BP 217, Grenoble, France.
authors.forename: P
authors.initials: P
authors.lastname: Bouzat
authors.forename: G
authors.initials: G
authors.lastname: Francony
authors.forename: P
authors.initials: P
authors.lastname: Declety
authors.forename: J
authors.initials: J
authors.lastname: Brun
authors.forename: A
authors.initials: A
authors.lastname: Kaddour
authors.forename: J-C
authors.initials: JC
authors.lastname: Renversez
authors.forename: C
authors.initials: C
authors.lastname: Jacquot
authors.forename: J-F
authors.initials: JF
authors.lastname: Payen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D001930:Brain Injuries / Q000097:blood* / Q000150:complications; D015986:Confounding Factors, Epidemiologic; D018450:Disease Progression; D005260:Female; D015600:Glasgow Coma Scale; D006801:Humans; D008297:Male; D008875:Middle Aged; D009104:Multiple Trauma / Q000097:blood; D009414:Nerve Growth Factors / Q000097:blood*; D011237:Predictive Value of Tests; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000097:blood*; D015599:Trauma Severity Indices; D055815:Young Adult
chemical_list: D015415:Biomarkers; D009414:Nerve Growth Factors; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins